U.S. FDA Wants More Information On AstraZeneca PLC Lung Drug
LONDON, Aug 30 (Reuters) - AstraZeneca's MedImmune biologics unit has been asked by U.S regulators for more information on its infant lung drug motavizumab after drug regulatory advisors recommended against approving it in June.